Canonical microRNA loss drives tumor development, implicating therapeutic efficacy of enoxacin in angiosarcoma

Read full text
Authors: Bozhi Liu, Ant Murphy, Annaleigh Benton, Lauren E. Gartenhaus, William Budka, Juliana M. Bronzini, Samuel Hartzler, Madison Yates, Alejandra Romero Alzate, Nimod D. Janson, Shyaman Jayasundara, Sagar M. Utturkar
+3 more Nadia A. Lanman, Majid Kazemian, Jason A. Hanna
Cited by: 0
References: 68

Abstract

Abstract Angiosarcoma (AS) is a rare and aggressive tumor arising within the endothelium, characterized by a high metastatic rate and poor prognosis. Our prior work established that endothelial loss of Dicer1 , a key enzyme in microRNA (miRNA) processing, drives AS formation in mice, indicating a tumor suppressive role for miRNAs in tumorigenesis. Here, we corroborated this hypothesis by generating a novel conditional knockout model targeting Dgcr8 , a core component of the microprocessor complex required for pri-miRNA processing. Conditional deletion of Dgcr8 phenocopies Dicer1 loss, resulting in spontaneous AS formation and global loss of mature miRNAs. We further demonstrate that treatment with enoxacin (ENX), a repurposed antibiotic known to enhance miRNA processing, reduces viability, migration, and clonogenicity of AS cells. ENX increases the abundance of tumor-suppressive miRNAs and downregulates oncogenic pathways, including pathways related to cell cycle progression, angiogenesis, and cell migration. These results establish the essential role of miRNA biogenesis in suppressing AS and reveal a pharmacologically targetable vulnerability via ENX-mediated enhancement of miRNA expression in tumors.

Fields of Study & Subjects

MicroRNA in disease regulation Vascular Tumors and Angiosarcomas Angiogenesis and VEGF in Cancer

Publication details

Journal / source
RNA
Volume
32
Issue
6
Pages
812–826
Publication date
26 February 2026
Language
EN